CD31 is a transhomophilic tyrosine-based inhibitory motif receptor and is expressed by both dendritic cells (DCs) and T lymphocytes. Previous studies have established that the engagement of CD31 drives immune-inhibitory signaling in T lymphocytes, but the effect exerted by CD31 signaling in DCs remains elusive. Here, we show that CD31 is a key coinhibitory receptor on stimulated DCs, favoring the development of tolerogenic functions and finally resulting in T-cell tolerance. The disruption of CD31 signaling favored the immunogenic maturation and migration of resident DCs to the draining lymph nodes. In contrast, sustaining the CD31/SHP-1 signaling during DC maturation resulted in reduced NF-κB nuclear translocation, expression of costimulatory molecules, and production of immunogenic cytokines (e.g., IL-12, IL-6), whereas the expression of TGF-β and IL-10 were increased. More importantly, CD31-conditioned DCs purified from the draining lymph nodes of ovalbuminimmunized mice favored the generation of antigen-specific regulatory T cells (CD25 + forkhead box P3 + ) at the expense of effector (IFN-γ + ) cells upon coculture with naive ovalbumin-specific CD4 + T lymphocytes ex vivo. Finally, the adoptive transfer of CD31-conditioned myelin oligodendrocyte glycoprotein-loaded DCs carried immune tolerance against the subsequent development of MOG-induced experimental autoimmune encephalomyelitis in vivo. The key coinhibitory role exerted by CD31 on DCs highlighted by the present study may have important implications both in settings where the immunogenic function of DCs is desirable, such as infection and cancer, and in settings where tolerance-driving DCs are preferred, such as autoimmune diseases and transplantation.
Edited by Ira Mellman, Genentech, Inc., South San Francisco, CA, and approved February 10, 2014 (received for review August 6, 2013) CD31 is a transhomophilic tyrosine-based inhibitory motif receptor and is expressed by both dendritic cells (DCs) and T lymphocytes. Previous studies have established that the engagement of CD31 drives immune-inhibitory signaling in T lymphocytes, but the effect exerted by CD31 signaling in DCs remains elusive. Here, we show that CD31 is a key coinhibitory receptor on stimulated DCs, favoring the development of tolerogenic functions and finally resulting in T-cell tolerance. The disruption of CD31 signaling favored the immunogenic maturation and migration of resident DCs to the draining lymph nodes. In contrast, sustaining the CD31/SHP-1 signaling during DC maturation resulted in reduced NF-κB nuclear translocation, expression of costimulatory molecules, and production of immunogenic cytokines (e.g., IL-12, IL-6), whereas the expression of TGF-β and IL-10 were increased. More importantly, CD31-conditioned DCs purified from the draining lymph nodes of ovalbuminimmunized mice favored the generation of antigen-specific regulatory T cells (CD25 + forkhead box P3 + ) at the expense of effector (IFN-γ + ) cells upon coculture with naive ovalbumin-specific CD4 + T lymphocytes ex vivo. Finally, the adoptive transfer of CD31-conditioned myelin oligodendrocyte glycoprotein-loaded DCs carried immune tolerance against the subsequent development of MOG-induced experimental autoimmune encephalomyelitis in vivo. The key coinhibitory role exerted by CD31 on DCs highlighted by the present study may have important implications both in settings where the immunogenic function of DCs is desirable, such as infection and cancer, and in settings where tolerance-driving DCs are preferred, such as autoimmune diseases and transplantation. + T-cell responses by recognizing and presenting specific antigens associated with danger signals (1, 2) . These signals contribute to conferring a fully mature, immunogenic phenotype to DCs, which is characterized by the up-regulation of MHC costimulatory molecules (e.g., CD40, CD86, CD80). The ensuing up-regulation of the chemokine (C-C motif) receptor type 7 (CCR7) receptor enables the migration of DCs to draining lymph nodes following the chemokine (C-C) motif ligand 21 (CCL21) gradient (3, 4) . Finally, the fully matured DCs produce the proinflammatory cytokines IL-1β, TNF, IL-12, and IL-6 (5). Importantly, DCs can also exert the opposite function by tolerizing T cells against self-antigen-directed immune responses, which is necessary to minimize autoimmune reactions. However, insufficient DC immunogenicity and excessive tolerance would favor the development of chronic infections and tumors. The immunogenic function of DCs depends on the balance between activating and inhibitory signals that occur at the time of DC maturation (2) .
Elucidating the inhibitory receptors that are involved in the control of DC maturation would facilitate new interventional strategies to control autoimmune diseases. Despite intensive work in this area (6) , the coinhibitory receptors involved in the control of DC immunogenic functions remain poorly understood.
Ig-like immunoreceptor tyrosine-based inhibitory motif (ITIM) receptors are thought to play an essential role in inhibiting the maturation of DCs (7) .
Among the Ig-like ITIM receptors, we propose that CD31 (8, 9) (also known as PECAM-1) may play an important role in DC function because CD31 is constitutively expressed on these cells (10) . Moreover, CD31 is essentially engaged by homophilic binding (11) , which remarkably occurs between interacting cells of the innate and adaptive immune system.
The low-affinity, transhomophilic engagement of CD31 (11) triggers downstream inhibitory signaling (9) , leads to the detachment of CD31 + lymphocytes from the cells of the innate immune system (12) , and raises the activation threshold of lymphocytes via the phosphorylation of CD31 ITIMs and the recruitment of SH2 domain-containing tyrosine phosphatase (e.g., SHP-1, SHP-2) upon the engagement of the antigen receptor (13) (14) (15) (16) . Nevertheless, the role played by CD31 in maturing DCs remains to be elucidated.
Interestingly, it has been shown that during LPS-driven maturation, CD31 expression is consistently reduced on human monocyte-derived DCs (17) (18) (19) and endotoxin-induced septic shock is exaggerated in CD31 −/− mice (20, 21) . In addition, autoimmune disease models dependent on antigen presentation are accelerated in the absence of CD31 (22, 23) , suggesting that the effective presentation of the immunizing antigens involved in specific adaptive immune responses is favored by the absence of CD31.
Significance
Much is known about the costimulatory receptors that contribute to the full maturation of DCs, whereas the coinhibitory receptors that are involved in the control of DC maturation and the maintenance of peripheral tolerance remain largely unknown. This work reveals that CD31, a transhomophilic coreceptor constitutively expressed by resting DCs, has a key coinhibitory function. CD31 is lost by maturing DCs, and the absence of CD31 favors immunogenic maturation. In contrast, upholding CD31 signaling during maturation converts stimulated DCs into tolerogenic cells. These findings will likely have a substantial impact on immunology research, because knowledge of the immune modulation of DCs is important in immune homeostasis as well as in communicable and noncommunicable diseases, including infection, autoimmunity, and cancer.
Here, we demonstrate that the disruption of CD31 signaling favors the maturation and subsequent migration of antigenloaded DCs to the draining lymphoid organs, driving more rapid and effective antigen-specific T-cell responses. In contrast, upholding the CD31/SH2 domain-containing tyrosine phosphatasesignaling pathway with an agonist peptide reduces the extent of maturation of the DCs, which become tolerogenic toward recall antigens both in vitro and in vivo.
Results
Disruption of CD31 Signaling Favors the Maturation and Accelerates the Migration of Antigen-Loaded DCs to the Draining Lymph Nodes.
One of the canonical features of DCs is their transport of antigens from tissues to draining lymph nodes. We therefore compared the activation-induced migration of DCs, using the FITC-painting assay, between CD31 +/+ and CD31 −/− mice (Fig. 1) . (Fig. 1A) . The maturation marker CD80 was consistently expressed by FITC + DCs (Fig. 1B) regardless of the presence of CD31, but the number of FITC + DCs that had reached the draining lymph node was significantly higher in the absence of CD31 (Fig. 1C) , and this increase was not explained by the expansion of a particular DC subset ( Fig. 1 D and E) . To assess whether the genetic deletion of CD31 affects DC migration, we evaluated the expression of CCR7 and the migratory response to CCL21 of bone marrow-derived DCs (BMDCs) derived from CD31 +/+ and CD31 −/− mice in vitro. As shown in Fig. S1 , the expression of CCR7, as well as the magnitude of CCL21-induced migration of CD31 −/− DCs, was similar to that of CD31 +/+ control DCs, regardless of the maturation state. Thus, the absence of CD31 does not increase the response of DCs to the CCL21 gradient but, rather, promotes DC migration indirectly via more efficient maturation upon LPS stimulation.
Indeed, the maturation of BMDCs [as detected by the acquisition of MHC class II (MHCII) and CD80 surface expression] was accompanied by a consistent reduction in CD31 surface expression ( Fig. 2A) . The extent of the maturation achieved by BMDCs was greater in the absence of CD31, as detected by an increased frequency of mature (CD86 + CD80 + ) DCs upon stimulation with a suboptimal (100 ng/mL) amount of LPS (Fig.  2B) . The expression level of additional maturation markers, such as MHCII and CD40, on the surfaces of mature (CD80   +   CD86 + ) DCs was higher in the absence of CD31 (Fig. 2C) , and all four markers were consistently expressed at higher densities on CD31 −/− LPS-stimulated BMDCs (Fig. 2D ). More striking was the production of inflammatory cytokines, which was enhanced three-to sixfold in the absence of CD31 in both unstimulated and LPSstimulated BMDCs (Fig. 2E ).
Maintenance of CD31 Signaling Thwarts DC Immunogenic Maturation.
CD31 signaling, which is triggered by transhomophilic interactions, depends on the establishment of membrane-proximal, cis-homophilic interactions (11) (e.g., CD31-molecule clusterization). CD31 signaling was thus artificially upheld in LPSstimulated DCs by using a synthetic peptide derived from the membrane-proximal extracellular sequence of the molecule (16). This peptide was able to prevent the internalization of endogenous CD31 molecules, which was promptly observed upon LPS stimulation, and concomitantly favored the formation of stable CD31 clusters on the surface of the stimulated DCs (Fig. 3A and Fig. S2 ). Furthermore, the engagement of CD31 molecules at the DC surface by the peptide promoted CD31 signaling, as detected by the tyrosine phosphorylation of SHP-2 (24) (25) (26) , to the same extent as antibody-mediated cross-linking of the endogenous CD31 molecules (Fig. 3B) . Upholding the CD31/SH2 phosphatase signaling with this peptide modified DC maturation both quantitatively and qualitatively. The expression of the costimulatory molecules MHCII, CD86, CD40, and CD80 (Fig. 3C ) and of the immunogenic cytokines IL-12 and IL-6 ( Fig. 3D ) was significantly reduced, whereas that of TGF-β1 and IL-10 was increased. The measure of soluble cytokines in the culture supernatant confirmed the dichotomy between the effects exerted by CD31 signaling on the production of proinflammatory and anti-inflammatory cytokines (Fig. 3E) . and Reduces NF-κB Nuclear Translocation. The CD31-dependent coinhibition of T cells involves the action of SHP-2 (24) . To identify whether the activation of SHP-2 that accompanies CD31 signaling also plays a functional role in the CD31-dependent coinhibition of DCs, we examined the effect of phenylhydrazonopyrazolone sulfonate (PHPS1). High doses of PHPS1 were necessary to prevent the inhibitory effect of CD31 signaling on LPS-driven IL-6 production by BMDCs (Fig. 4A) , suggesting that another SH2 domain-containing tyrosine phosphatase was involved in the coinhibitory signaling pathway downstream of CD31 in DCs. In addition to SHP-2, the ITIMs of CD31 can recruit and activate SHP-1 (13) . Our data show that the CD31 coinhibition of DCs is indeed mediated by the activity of SHP-1, because low doses of sodium stibogluconate (SSG), which specifically inhibits SHP-1, were able to abolish the negative effect of CD31 signaling on IL-6 production (Fig. 4A ). In addition, the peptide was ineffective in reducing IL-6 production by SHP-1 −/− BMDCs (Fig. 4B) . SHP-1 has recently been highlighted as a key molecule in the regulation of DC function (27) , notably through the inhibition of the signaling pathway leading to the nuclear translocation of NF-κB, a fundamental activation step downstream of LPS stimulation (28) . The pharmacological inhibition of NF-κB effectively blocked the phenotypic maturation of DCs (Fig. 4C) , as expected. In agreement with its inhibitory function, the absence of CD31 resulted in an eightfold increased production of IL-6 compared with CD31 +/+ cells. The effective inhibition of IL-6 production in these cells by the NK-kB inhibitors suggested that CD31 coinhibitory signaling involves a regulatory step on NF-κB translocation. Immunohistochemistry and cytometric analyses of nuclei preparations supported this hypothesis by showing that the CD31 peptide effectively reduces the extent of NF-κB p65 translocation to the DC nucleus during LPS stimulation (Fig. 4 D-F) . This process can explain, at least in part, why CD31 signaling results in the reduction of DC proinflammatory cytokines and costimulatory molecules.
Engagement of CD31 on DCs Affects Their Migration in Vivo. To assess whether CD31 engagement affects DC function in vivo, we first tracked the CD31 agonist in situ, after a single s.c. injection, by using a fluorescein-conjugated peptide (FAM-CD31 peptide) and immunofluorescence confocal microscopy. These experiments showed that the CD31 peptide effectively targets the CD11c + cells (DCs) of the skin (Fig. 5A ). Cytometric analysis of −/− BMDCs also released greater amounts of soluble (in the supernatant) proinflammatory cytokines in response to LPS. Regarding surface costimulatory molecule expression, no differences were observed in terms of cytokine production between the two strains in basal (unstimulated) culture conditions. *P < 0.05, **P < 0.01 vs. CD31
. The data are expressed as the average ± SEM of the MFI of each parameter obtained from five independent experiments (n ≥ 3 mice per strain in all experiments); individual data were used for analysis. ). Of note, pSHP-2 Y542 was consistently reduced in CD31 −/− DCs, whereas it was significantly increased upon antibody-mediated crosslinking as well as by the CD31 peptide only in CD31 +/+ cells. These data indicate that the CD31 peptide 551-574 is a CD31 receptor agonist. **P < 0.01. (C) Cytometric analysis of MHCII, CD40, CD86, and CD80 expression on BMDCs incubated overnight with LPS (1 μg/mL) revealed that upholding CD31 signaling with the CD31 agonist peptide (50 μg/mL) results in reduced DC maturation, as detected by the reduction of costimulatory molecule expression levels. Filled histogram, no LPS; black line, LPS; red line, LPS + CD31 peptide. FSC, forward side scatter; NS, not significant. **P < 0.01. (D) Time course of proinflammatory and anti-inflammatory cytokine gene expression by real-time PCR showed that the CD31 agonist peptide significantly reduced the expression of IL-12 and IL-6, whereas it increased the expression of TGF-β1 and IL-10 by LPS-stimulated BMDCs. The data are expressed as 2 -ΔΔCt (43) . (E) LPS-induced production of proinflammatory cytokines, but not of IL-10, by BMDCs was consistently reduced in the presence of the CD31 peptide. **P < 0.01. The data are from three separate preparations per condition. All of the experiments were repeated at least twice and provided similar results.
the skin and draining lymph node cells 1 h after the injection showed that the CD31 peptide targets virtually all skin DCs and a small portion of lymph node DCs (Fig. 5B) . The CD31 peptide mainly bound to the myeloid CD103 − and lymphoid CD8 − CD4 − DC subsets in the skin. A small percentage (∼20%) of DCs within draining lymph nodes, mostly lymphoid DCs, were also positive for the presence of the FAM-CD31 peptide (Fig. 5C ).
To evaluate the effect of CD31 signaling on DCs involved in active immunization protocols, we evaluated the subsets of skin and draining lymph node DCs before and after immunization with complete Freund's adjuvant (CFA). As shown in Fig. 5D , CFA immunization induced the migration of myeloid CD103 − DCs from the skin to the draining lymph nodes. Of note, plasmacytoid DCs were enriched in the skin upon immunization, and this DC subset was particularly targeted by the fluorescent CD31 peptide, as shown in Fig. 5E . Interestingly, the FITC-painting assay was mainly associated with the migration of myeloid CD11b + CD103 − and lymphoid CD4 − CD8 − DCs from the skin to the draining lymph node, and upholding CD31 signaling with the agonist peptide actually reduced the percentage of migrating DCs in both of these main subsets (Fig. 5F ).
Taken together, these findings suggest that CD31 signaling acts as a coinhibitory receptor that impairs the maturation and subsequent migration of DCs.
CD31-Conditioned DCs Redirect the Differentiation of Cognate CD4
+ T Cells Toward a Regulatory Phenotype. To assess whether the modification of the maturation phenotype and migration of the DCs obtained in the presence of the agonist CD31 peptide can affect subsequent DC function in eliciting antigen-specific T-cell responses, we evaluated the proliferation and intracellular cytokine production of naive ovalbumin (OVA)-specific CD4 + T cells cocultured with BMDCs that had been stimulated overnight with LPS and OVA in the presence of the CD31 peptide or the vehicle. The production of IL-2 by OT-II cells was considerably reduced in the presence of CD31-conditioned BMDCs compared with control BMDCs (Fig. 6A ). In addition, CD31-conditioned BMDCs prevented the production of the effector cytokine by the OT-II cells (IFN-γ, as detected by intracellular cytokine staining; Fig. 6B ).
We next aimed to evaluate whether similar modulatory effects of CD31 could affect the development of antigen-elicited immunogenic DCs in vivo. Toward this aim, we used ex vivo FACSpurified DCs derived from EGFP-transgenic (Tg) mice that were pretreated or not pretreated with the CD31 agonist peptide (termed "CD31 DC" henceforth) before OVA immunization in vivo. The FACS-purified DCs from the pooled draining lymph nodes (axillary and inguinal) were cocultured with purified naive (CD44 − CD25 − CD62L high ) OT-II CD4 + T cells that were prestained with a violet cell-proliferation tracker [CellTrace Violet (CTV) Cell Proliferation Kit; Life Technologies]. The protocol is schematized in Fig. 6C . As shown in Fig. 6D , the proliferative response of OT-II CD4 + T cells was significantly reduced if the OVA antigen was presented by CD31 DCs. Interestingly, whereas the production of soluble IL-2, IFN-γ, and IL-17A followed the same trend as the proliferative response, IL-10 levels were unaltered in the supernatants of OT-II CD4 + T cells stimulated with CD31 DCs. Furthermore, the percentage and proliferation rate of regulatory T cells (Tregs), detected as CD25 high FoxP3 + OT-II CD4 + T cells, elicited by CD31 DCs were significantly increased (Fig. 6E) . These results suggest that CD31 DCs can drive a tolerogenic T-cell response by skewing the differentiation of the cognate antigen-specific T cells toward a regulatory phenotype. The functional suppressive nature of CD31 DC-elicited Tregs was directly assessed in "cascade" experiments in which CD4 + CD25 high cells were purified from CD31 DC/OT-II T-cell cocultures and transferred to fresh cocultures of freshly purified spleen DCs with OT-II cells and OVA. As shown in Fig. 6F , CD31 DC-elicited CD4 + CD25 high cells suppressed the production of (10 5 per condition) were preincubated for 30 min with SHP-1/2 inhibitors (10 μM PHPS1, which specifically inhibits SHP-2; 100 μM PHPS1, which inhibits both SHP-1 and SHP-2; and 10 μM SSG, which specifically inhibits SHP-1) and subsequently supplemented with LPS (1 μg/mL) and the CD31 peptide (50 μg/mL) or vehicle. Unstimulated (Unstim) cells were used as a control. CBA analysis of IL-6 concentration in the supernatant of the different experimental conditions (expressed as a percentage of the mean values obtained in LPSstimulated BMDCs) showed that CD31-driven signaling in DCs is mediated by SHP-1, because only low doses of SSG abolished the inhibitory effect of the CD31-agonist peptide on IL-6 production. *P < 0.05. (B) BMDCs derived from WT and SHP-1 −/− mice were stimulated with LPS (1 μg/mL) with or without the CD31 peptide at the indicated concentration overnight. Analysis of IL-6 content in the supernatant of these experiments indicated that SHP-1 is essential for CD31 peptide activity. *P < 0.05. (C) Use of the NF-κB inhibitors [20 μM Bay 11, 50 μM ammonium pyrrolidinedithiocarbamate (PDTC)] completely inhibited the production of IL-6 by both CD31 +/+ and CD31 −/− LPS-stimulated BMDCs.
NF-κB inhibitors completely blocked IL-6 production by CD31 −/− cells despite the fact that these cells produced significantly greater amounts of the cytokine compared with CD31 +/+ LPS-stimulated BMDCs, suggesting that CD31 may exert its coinhibitory effects on DCs by having an impact on NF-κB activation. *P < 0.05. (D) Representative example of intracellular NF-κB p65 immunofluorescent staining of fixed-permeabilized DCs based on confocal microscopic analysis. Phalloidin (green) and Hoechst (blue) counterstaining was used to localize the cell surface and the nuclei, respectively. NF-κB p65 staining was concentrated in the nucleus of LPS-stimulated DCs, whereas the staining was only visible in the cytoplasm of unstimulated cells. Interestingly, the presence of the CD31-agonist peptide prevented this phenomenon; NF-κB p65 distribution appeared diffuse in this condition. 
IFN-
Adoptive Transfer of CD31-Conditioned DCs Significantly Delays the Development of Myelin Oligodendrocyte Glycoprotein-Driven Autoimmune Encephalomyelitis in Mice. We next used the BMDC adoptive transfer strategy with the myelin oligodendrocyte glycoprotein (MOG) peptides 35-55 to assess the effect of CD31-conditioned DCs on the development of autoimmune responses in vivo in the MOG-induced experimental autoimmune encephalomyelitis (EAE) model (Fig. 7) . MOG-specific CD4 + T-cell clones that were elicited in mice receiving CD31 BMDCs produced less IL-2, IFN-γ, IL-17A, and IL-6 cytokines upon MOG-recall challenge in vitro, whereas the soluble levels of IL-4 and IL-10 in culture supernatants were not affected (Fig. 7A) . In vivo tracking showed that CD31 BMDCs adoptively transferred by s.c. injection in the flanks of mice do reach the draining lymph nodes (axillary and inguinal), but in fewer numbers (Fig. 7B) .
However, the blunted immune response observed following the transfer of CD31-conditioned DCs is not due merely to the lower number of DCs that reach the lymph node. Indeed, the adoptive transfer of either immature BMDCs or MOG-activated BMDCs did not affect the development of experimental EAE induced by MOG immunization in vivo. Instead, the clinical manifestations of the autoimmune response were consistently delayed in mice that had been adoptively transferred with CD31 DCs (Fig. 7C) , which displayed significantly milder clinical signs of EAE than any other study groups for at least 3 d, suggesting that the DCs exerted a different effect than the endogenous cells. This issue was directly assessed in titration experiments in which lower numbers of antigen-loaded BMDCs were adoptively transferred to experimental mice (Fig. 8A) . As expected, reducing the number of injected antigen-loaded BMDCs results in milder antigen-specific T-cell proliferative and effector cytokine responses (Fig. 8 B and C) . However, only CD31-conditioned BMDCs concomitantly favored the enrichment of antigen-specific Tregs in the draining lymph node; the number of Tregs remained low in the lymph nodes of mice receiving OVAloaded BMDCs at all of the tested cell dilutions (Fig. 8D) . Finally, we observed that the adoptively transferred BMDCs exerted their effect directly, as detected with CTV-labeled BMDCs in GFP-Tg mice and with subsequent DC purification and functional testing in vitro (Fig. 8D) . As expected, only exogenous BMDCs were able to elicit the production of effector cytokines in functional tests, provided that they had not been conditioned with CD31. Discussion CD31 is an important, yet neglected, immune inhibitory receptor (8, 9, 29) . Because of its extracellular Ig-like domains and localization in the lateral junctions between endothelial cells in the vasculature (30) , CD31 was initially viewed as a putative celladhesion molecule, and the ability of CD31-targeting antibodies or recombinant proteins (31, 32) to inhibit leukocyte transmigration has long supported this perception. However, the absence of CD31 does not reduce the transmigration of blood leukocytes (33) but, rather, promotes CD4 + T-cell recruitment at inflammatory sites (23) .
Several subsequent experimental studies have clearly demonstrated that CD31 plays important inhibitory signaling roles in effector-adaptive immune cells, such as T and B lymphocytes (14, 15, 24, (34) (35) (36) (37) . More recent studies have suggested that the homophilic engagement of CD31 between DCs and cognate T cells may establish the threshold for T-cell activation and tolerance (35) , but the role played by this ITIM receptor in DC function has remained elusive.
In this study, we show that CD31 acts as a key coinhibitory receptor and dramatically modulates the function of DCs, independent of its already known regulatory function on other immune effectors. Whereas the reduction of CD31 molecules at the cell surface is a prerequisite for the immunogenic potential of DCs because it favors their maturation, accelerates their migration to the lymph nodes, and increases their production of proinflammatory cytokines, upholding CD31 signaling thwarts the immunogenic functions of DCs, instead favoring the generation and expansion of regulatory cognate T cells at the expense of the effector phenotype.
Interestingly, our data suggest that the engagement of surface CD31 on DCs is a key trigger for the regulatory signaling cascade that is mediated by SHP-1 and modulates NF-κB activation and cytokine production (27) .
The identification of the role played by CD31 during DC maturation in this study may thus have a broad impact in several research fields in immunobiology, wherever the immunogenic function of DCs is desirable or unwanted. For instance, the fact that CD31 surface expression is reduced on human DCs upon their interaction with LPS (17-19) and/or bacterial proteolytic enzymes (38) suggests that the invalidation of this coinhibitory receptor is necessary for the development of protective adaptive immune responses against bacteria. Similarly, interventional tools able to invalidate CD31 signaling may enhance the success of vaccination therapies in cancer. Indeed, the acquisition of CD31 by tumoral cells (39) might be one mechanism by which tumor cells can engage the CD31 molecules of DCs, leading to a blunted immunogenic potential of DCs and, consequently, a flawed immune defense against cancer. FITC-Painting Assay. The draining lymph node DCs were analyzed after FITC skin painting as described previously (41) . Briefly, FITC (isomer 1; SigmaAldrich) was dissolved (8 mg/mL) in a 50:50 (vol/vol) acetone-dibutyl phthalate mixture just before application. This FITC solution was distributed in six spots (25 μL per spot) on the shaved back skin of anesthetized mice. Mice treated with the CD31 peptide were injected s.c. with 100 μg per mouse in four spots 1 h before FITC painting. Twenty hours later, the draining lymph nodes (inguinal, brachial, and axillary) and nondraining lymph nodes (popliteal) were removed (the left and right lymph nodes from each mouse were analyzed separately) and placed in a collagenase D (Roche) solution (1 mg/mL in RPMI) for 30 min. The enzymatic digestion was stopped by the addition of Analysis of Gene Expression by Real-Time PCR. BMDCs were seeded on 96-well, round-bottom plates at 1 × 10 5 cells per well. CD31 peptide and LPS were added at different time points as indicated. Total RNAs were extracted using TRIzol (Life Technologies), and mRNA reverse transcription was performed using iScript reverse transcriptase (Bio-Rad). Real-time PCR was performed on a CFX 100 (Bio-Rad) cycler using the primers listed in Table 1 , 1 ng of cDNA from each sample in a total volume of 22 μL containing the forward and reverse primers (250 nM each), and SYBR Green Master Mix (Bio-Rad). The amplification program was as follows: one cycle at 50°C for 2 min, one cycle at 95°C for 15 min, and 50 cycles at 95°C for 40 s and 60°C for 1 min. Dissociation curves were analyzed at the end of the amplification, and data concerning the genes of interest were normalized by the expression of the β-actin gene in the same condition and were expressed compared with a control condition with no LPS and no CD31 peptide. The 2 -ΔΔCt formula described by Pfaffl (43) was applied, where threshold cycle (Ct) values correspond to the cycle at which the PCR enters the exponential phase.
Immunofluorescence Microscopy. CD31. BMDCs were harvested 8 d after their differentiation, plated on Ibidi eight-well μ-Slides (2 × 10 5 cells per well), and allowed to adhere overnight. After careful washing, adherent cells were precooled on ice for 30 min and stained with an anti-mouse CD31 antibody [clone Mec13.3, directly coupled to phycoerythrin (PE)] for 30 min on ice. Thereafter, the cells were washed in ice-cold PBS and warmed up to 37°C with complete medium containing or not containing LPS (1 μg/mL) and the CD31 peptide (100 μg/mL). The cells were allowed to stabilize for 5 min before image acquisition. CD31 BMDC, OVA cells was significantly higher than that elicited by BMDC, OVA cells at all tested cell dilutions. *P < 0.05. (E) Evaluation of the direct and indirect effects of CTV-labeled BMDCs adoptively transferred to GFP-Tg mice was performed by assessing the properties of FACS-purified DCs. Adoptively transferred BMDCs (CTV + ) were able to elicit an antigen-specific immune response (production of IL-2, IFN-γ, and TNF), whereas endogenous DCs (GFP + ) were ineffective, regardless of their positivity for CTV (possibly indicating the phagocytosis of exogenous BMDCs). As before, CD31 BMDCs did not elicit an antigen-specific response in terms of effector cytokine production. At least three mice per group were used in these experiments, which were repeated twice, with similar results. **P < 0.01. NF-κB. BMDCs (2 × 10 5 ) were carefully washed, resuspended, and stimulated for 30 min at 37°C in FCS-free medium with LPS (250 ng/mL) with or without the CD31 peptide (50 μg/mL). Unstimulated cells were used as a control. At the end of the stimulation, the cell suspensions were layered onto polylysine-coated coverslips and allowed to adhere for 30 min at 37°C. The coverslips were then washed twice with warm FCS-free medium, and the adherent cells were fixed with PBS/4% (wt/vol) paraformaldehyde (PFA; 15 min at room temperature) and incubated for 10 min with glycine (100 mM in PBS, pH 7.4) to quench residual aldehydes. The cell and nuclear membranes were then permeabilized with PBS/0.5% Triton X-100 for 10 min and extensively washed in PBS/0.5% Triton X-100/1% BSA before incubation with purified polyclonal rabbit anti-mouse NF-κB p65 antibody (no. ab16502, Abcam; diluted at 5 μg/mL in PBS/0.5% Triton X-100/1% BSA) for 90 min at room temperature. The coverslips were then extensively washed with PBS/ 0.5% Triton X-100/1% BSA and incubated for 30 min with 7.5 μg/mL TRITC-conjugated AffiniPure F(ab′)2 Fragment Rabbit Anti-Goat IgG, Fc Fragment-Specific (no. 305-026-008; Jackson ImmunoResearch Laboratories) and 1 unit of Alexa Fluor 488 Phalloidin (Life Technologies) diluted in the same buffer. After extensive washing, the cells were incubated for 5 min with 1 μg/mL Hoechst 33342 (Life Technologies) in PBS, washed twice in PBS, and cover-mounted with ProLong Gold Antifade Reagent (Life Technologies) before image acquisition.
Digital images were acquired using AxioVision software and a Zeiss Axio Observer Z1 microscope equipped with an ApoTome. Fluorescence-intensity analysis of the digital images was performed using ImageJ (National Institutes of Health). In separate experiments, GFP-Tg mice were adoptively transferred with CTV-labeled BMDCs (5 × 10 6 per mouse by intradermal injection). To achieve this aim, BMDCs were prepared as previously described and stimulated overnight with LPS (1 μg/mL) in the presence of OVA protein (30 μg/mL, no. A5503; Sigma) and with or without the CD31 peptide (100 μg/mL). The mice were euthanized after an overnight period, and the lymph nodes draining the site of injection were harvested and digested in collagenase D (1 mg/mL final concentration; Roche). Single-cell suspensions were washed and incubated with an anti-mouse CD11c antibody (clone HL3, PE-CF594; BD Biosciences) for 30 min on ice in PBS. The cells were then washed and submitted for FACS purification, yielding three populations of CD11c Finally, the samples were extensively washed in in PBS/2% (vol/vol) Triton X-100/ 20% (vol/vol) DMSO, cleared, and mounted as previously described for wholemount mouse embryos (44) . Digital images were acquired using AxioVision software and a Zeiss Axio Observer Z1 microscope equipped with an ApoTome. Fluorescence-intensity analysis of the digital images was performed using ImageJ software. In separate experiments, flow cytometry was used to evaluate the DC subsets that were bound to the fluorescent peptide. To achieve this aim, the fluorescent CD31 peptide (100 μg in four dots per mouse) was injected s.c. Adoptive Transfer of CD31-Conditioned DCs. Migration from the skin to draining lymph nodes. BMDCs from C57BL/6 mice were left untouched or stimulated overnight with LPS (1 μg/mL) with or without CD31 peptide (50 μg/mL). The cells were then washed and stained with CTV (5 μM). Recipient mice (three groups: "BMDC"; "BMDC, MOG"; and "CD31 BMDC, MOG") received 100 μL (administered s.c.) of the appropriate cell suspension (5 × 10 6 BMDCs per mouse). On the next day, the mice were killed under anesthesia and cell suspensions were prepared from the draining lymph nodes as described previously. The CTV + cells were analyzed by cytometry among the DCs (identified by staining with PE-conjugated anti-CD11c antibody). Immune function upon antigenic recall challenge in vitro. BMDCs from C57BL/6 mice were either left untouched or incubated with 50 μg/mL MOG 35-55 peptide (amino acids 35-55, MEVGWYRSPFSRVVHLYRNGK; PolyPeptide Laboratories) during an overnight stimulation with LPS (1 μg/mL) with or without CD31 peptide (50 μg/mL), yielding two types of DCs: MOG-loaded mature DCs (BMDC, MOG) and MOG-loaded mature and CD31-conditioned DCs (CD31 BMDC, MOG). Five million cells from each condition were adoptively transferred s.c. into the flanks of C57BL/6 recipient mice, as described above. Ten days after the BMDC adoptive transfer, the draining lymph nodes were harvested, digested, and meshed, and the cells were counted and incubated at 5 × Comparison of immunogenic/tolerogenic properties of untreated and CD31-conditioned BMDCs. BMDCs were prepared as described above, washed, and incubated overnight in complete medium containing LPS (1 μg/mL) and OVA protein (50 μg/mL) and supplemented or not supplemented with the CD31 peptide (100 μg/mL) at a density of 5 × 10 6 cells per milliliter. Antigen-loaded DCs were thereafter extensively washed with ice-cold PBS, diluted at the indicated concentration, and s.c. injected into C57BL/6 mice that had received, an i. Intracellular staining of FoxP3 (PE-conjugated, clone PE-FJK-16s; eBiosciences) was performed according to the manufacturer's instructions after the cell surface was stained for CD4 and CD25.
Intracellular IFN-γ and IL-17A were assessed using a Mouse Th1/Th2/Th17 Phenotyping Kit (BD Biosciences) following the manufacturer's instructions.
Intracellular phosphorylation of SHP-2 was assessed in BMDCs incubated at 37°C with 200 ng/mL LPS for 15 min in the presence or absence of the CD31 peptide (5 × 10 6 BMDCs in 100 μL of IMDM per condition). The positive control for CD31-driven SHP-2 phosphorylation was obtained using a rat anti-mouse CD31 antibody (10 μg/mL, clone MEC13.3; BD Biosciences) and goat anti-rat IgG (Fab′) 2 fragments (100 μg/mL; Jackson Laboratories). CD31
−/− cells were used as the negative control. Intracellular staining with an anti-SHP-2 (pY542)-PE antibody (clone L99-921; BD Biosciences) or isotype control was performed on fixed/permeabilized cells (BD Phosflow Perm Buffer IV; BD Biosciences) following the manufacturer's instructions. Cytometric analysis of nuclear NF-κB in LPS-stimulated BMDCs was performed on purified nuclei obtained as described online by the Telford laboratory (http://home.ccr.cancer.gov/med/flowcore/nuclei.pdf). Briefly, BMDCs were harvested from the Petri dish and resuspended at a density of 5 × 10 6 cells per milliliter in IMDM supplemented with 10 −5 M β-mercaptoethanol, 2 mM L-glutamine, and 1× antibiotic/antimycotic solution. The cell suspensions (200 μL) were stimulated with LPS (250 ng/mL) with or without CD31 peptide (50 μg/mL) for 45 min at 37°C. The cells were then pelleted at 4°C (500 × g for 5 min), washed twice with cold PBS, gently resuspended, and incubated for 10 min on ice in 1 mL of cold nuclear extraction buffer [320 mM sucrose, 5 mM MgCl 2 , 10 mM Hepes, 1% Triton X-100 (pH 7.4)]. Next, the nuclei were pelleted (2,000 × g for 10 min) and washed twice with cold nuclear wash buffer [320 mM sucrose, 5 mM MgCl 2 , 10 mM Hepes (pH 7.4)]. This extraction procedure provided >98% nuclear purity without any clumping. The nuclei were then incubated for 2 min at room temperature with RNase A (100 U/mL; Qiagen) in nuclear wash buffer, washed, fixed in PBS/4% (wt/vol) PFA for 10 min, and washed twice with nuclear wash buffer. The fixed nuclei were then resuspended in nuclear extraction buffer containing 5 μg/mL purified polyclonal rabbit anti-mouse NF-κB p65 (no. ab16502; Abcam) and incubated overnight at 4°C. After two washes in nuclear wash buffer, the secondary antibody (goat anti-rabbit IgG conjugated to Dylight 649, Jackson ImmunoResearch) was added to nuclear extraction buffer supplemented with 0.5% BSA and incubated with the samples for 1 h at room temperature. The nuclei were then washed with nuclear extraction buffer and again with the nuclear wash buffer. Nuclear counterstaining was performed with 1 μg/mL DAPI in wash buffer supplemented with 0.5% BSA for 5 min. Thereafter, the nuclei were washed extensively, resuspended in wash buffer supplemented with 0.5% BSA, and analyzed. The cytometric acquisition and analysis were performed with an LSRII flow cytometer equipped with three lasers (405, 488, and 633 nm) and BD FACSDiva Software 6.0 (both from BD Biosciences), respectively. Statistical Analysis. The results are expressed as the mean ± SEM. The differences between the groups were evaluated by one-way ANOVA with Fischer's post hoc tests or by Mann-Whitney nonparametric tests as appropriate. Any differences between the groups were considered to be significant when the P value was <0.05 (*P < 0.05; **P < 0.01). The analysis was performed with JMP 6.0 Software (SAS Institute, Inc.).
